Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells
出版年份 2018 全文链接
标题
Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells
作者
关键词
-
出版物
eLife
Volume 7, Issue -, Pages -
出版商
eLife Sciences Organisation, Ltd.
发表日期
2018-01-09
DOI
10.7554/elife.29747
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
- (2016) Marc Hafner et al. NATURE METHODS
- Managing risks in drug discovery: reproducibility of published findings
- (2016) Aimo Kannt et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function
- (2016) Andre Kleensang et al. Scientific Reports
- Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2016) John P Vanden Heuvel et al. eLife
- Replication-induced DNA damage after PARP inhibition causes G2delay, and cell line-dependent apoptosis, necrosis and multinucleation
- (2015) Idun Dale Rein et al. CELL CYCLE
- PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
- (2015) F. Engert et al. MOLECULAR CANCER THERAPEUTICS
- The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
- (2015) José Luis Ordóñez et al. Oncotarget
- Conducting Meta-Analyses inRwith themetaforPackage
- (2015) Wolfgang Viechtbauer Journal of Statistical Software
- Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
- (2015) Sonja J. Gill et al. PLoS One
- Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
- (2014) Edwin Choy et al. BMC CANCER
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
- (2014) M. A. Smith et al. CLINICAL CANCER RESEARCH
- Refinement of Experimental Design and Conduct in Laboratory Animal Research
- (2014) J. D. Bailoo et al. ILAR JOURNAL
- Policy: NIH to balance sex in cell and animal studies
- (2014) Janine A. Clayton et al. NATURE
- Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program:PALB2mutation predicts exceptionalin vivoresponse to BMN 673
- (2014) Malcolm A. Smith et al. PEDIATRIC BLOOD & CANCER
- Targeting the DNA Repair Pathway in Ewing Sarcoma
- (2014) Elizabeth Stewart et al. Cell Reports
- An open investigation of the reproducibility of cancer biology research
- (2014) Timothy M Errington et al. eLife
- Effects of hypoxia on human cancer cell line chemosensitivity
- (2013) Sara Strese et al. BMC CANCER
- BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
- (2013) Britta Stordal et al. Molecular Oncology
- Power failure: why small sample size undermines the reliability of neuroscience
- (2013) Katherine S. Button et al. NATURE REVIEWS NEUROSCIENCE
- Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors
- (2013) Robin E. Norris et al. PEDIATRIC BLOOD & CANCER
- PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
- (2012) J. C. Brenner et al. CANCER RESEARCH
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- NIH Image to ImageJ: 25 years of image analysis
- (2012) Caroline A Schneider et al. NATURE METHODS
- Atmospheric Oxygen Inhibits Growth and Differentiation of Marrow-Derived Mouse Mesenchymal Stem Cells via a p53-Dependent Mechanism: Implications for Long-Term Culture Expansion
- (2012) Siddaraju V. Boregowda et al. STEM CELLS
- The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
- (2010) V. J. Weston et al. BLOOD
- Guidelines for accurate EC50/IC50 estimation
- (2010) J. L. Sebaugh PHARMACEUTICAL STATISTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started